ASX - By Stock
|
CYP |
Re:
Ann: DFU Clinical Trial Enrolment Complete
|
|
truss20
|
22 |
5.4K |
7 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
5.4K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
3 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
61
|
10K
|
3
|
|
ASX - By Stock
|
EML |
Re:
Ann: EML Announces Sale of Sentenial Business
|
|
truss20
|
66 |
22K |
1 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
66
|
22K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
2 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
61
|
10K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
2 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
61
|
10K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
3 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
61
|
10K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
The Phase I/IIb Nereid Study Is Now Registered
|
|
truss20
|
19 |
3.0K |
4 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
19
|
3.0K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
2 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
61
|
10K
|
2
|
|
ASX - By Stock
|
EML |
Re:
Ann: EML Announces Sale of Sentenial Business
|
|
truss20
|
66 |
22K |
5 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
66
|
22K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
The Phase I/IIb Nereid Study Is Now Registered
|
|
truss20
|
19 |
3.0K |
5 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
19
|
3.0K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
truss20
|
2.1K |
676K |
6 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
2.1K
|
676K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
truss20
|
2.1K |
676K |
6 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
2.1K
|
676K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
truss20
|
2.1K |
676K |
4 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
2.1K
|
676K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
61
|
10K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
truss20
|
2.1K |
676K |
8 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
2.1K
|
676K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
4 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
61
|
10K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
6 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
61
|
10K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
6 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
61
|
10K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First Patient Treated in Phase 2 GvHD Trial
|
|
truss20
|
61 |
10K |
7 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
61
|
10K
|
7
|
|
ASX - By Stock
|
EML |
Re:
Ann: H1FY24 Investor Presentation
|
|
truss20
|
60 |
25K |
4 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
60
|
25K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
truss20
|
49 |
9.8K |
9 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
49
|
9.8K
|
9
|
|
ASX - By Stock
|
EML |
Re:
Ann: H1FY24 Investor Presentation
|
|
truss20
|
60 |
25K |
9 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
60
|
25K
|
9
|
|
ASX - By Stock
|
EML |
Re:
Ann: H1FY24 Investor Presentation
|
|
truss20
|
60 |
25K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
60
|
25K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
truss20
|
49 |
9.8K |
7 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
9.8K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
truss20
|
49 |
9.8K |
11 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
9.8K
|
11
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Encouraging Initial Data from CYP-006TK DFU Trial
|
|
truss20
|
49 |
9.8K |
10 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
49
|
9.8K
|
10
|
|
ASX - By Stock
|
CYP |
Re:
TA
|
|
truss20
|
20 |
5.1K |
3 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
20
|
5.1K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
TA
|
|
truss20
|
20 |
5.1K |
7 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
20
|
5.1K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
truss20
|
21 |
5.4K |
3 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
21
|
5.4K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
truss20
|
37 |
12K |
5 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
37
|
12K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
truss20
|
37 |
12K |
8 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
37
|
12K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
truss20
|
21 |
5.4K |
13 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
21
|
5.4K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
truss20
|
514 |
117K |
7 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
514
|
117K
|
7
|
|
ASX - By Stock
|
EML |
Re:
Ann: EML Payments to exit 'PCSIL' business
|
|
truss20
|
71 |
34K |
3 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
71
|
34K
|
3
|
|
ASX - By Stock
|
EML |
Re:
Ann: EML Payments to exit 'PCSIL' business
|
|
truss20
|
71 |
34K |
3 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
71
|
34K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Initial Results in First 16 DFU Patients Expected in Q1 2024
|
|
truss20
|
37 |
12K |
8 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
37
|
12K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: First USA site initiated in aGvHD trial
|
|
truss20
|
31 |
8.0K |
7 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
31
|
8.0K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
FUJIFILM CDI Facility
|
|
truss20
|
3 |
1.2K |
8 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
3
|
1.2K
|
8
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y - Dr Kilian Kelly
|
|
truss20
|
12 |
3.5K |
4 |
24/11/23 |
24/11/23 |
ASX - By Stock
|
12
|
3.5K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Y - Dr Kilian Kelly
|
|
truss20
|
12 |
3.5K |
3 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
12
|
3.5K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 3Ys x 5
|
|
truss20
|
4 |
1.2K |
12 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
4
|
1.2K
|
12
|
|
ASX - By Stock
|
CYP |
Re:
AGM voting
|
|
truss20
|
43 |
8.6K |
5 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
43
|
8.6K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Dealmaking regarding DFU
|
|
truss20
|
1 |
445 |
3 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
1
|
445
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
truss20
|
8 |
1.7K |
7 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
8
|
1.7K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
truss20
|
8 |
1.7K |
6 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
8
|
1.7K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Dr David Atkins not to stand for re-election at AGM
|
|
truss20
|
6 |
1.7K |
6 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
6
|
1.7K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Webinar Presentation
|
|
truss20
|
8 |
2.4K |
5 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
8
|
2.4K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Webinar Presentation
|
|
truss20
|
8 |
2.4K |
7 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
8
|
2.4K
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 4E & Annual Report
|
|
truss20
|
15 |
5.6K |
6 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
15
|
5.6K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Appendix 4E & Annual Report
|
|
truss20
|
15 |
5.6K |
1 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
15
|
5.6K
|
1
|
|